The clinical utility of mass spectrometry based protein assays

Clinica Chimica Acta

Volumn 459, Issue , 2016, Pages 155-161

  Lassman, Michael E ^a   McAvoy, Thomas ^a   Chappell, Derek L ^a   Lee, Anita Y ^a   Zhao, Xuemei X ^a   Laterza, Omar F ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Application; Mass spectrometry; Peptide; Protein; Review

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN; PROTEIN;

CLINICAL LABORATORY; CLINICAL RESEARCH; HUMAN; INTERMETHOD COMPARISON; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN TARGETING; REVIEW; SEPARATION TECHNIQUE; KINETICS; METABOLISM;

BIOMARKERS; HUMANS; KINETICS; MASS SPECTROMETRY; PROTEINS;

EID: 84973441962     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.05.027     Document Type: Review

References (119)

1. Krumpochova P., Bruyneel B., Molenaar D., Koukou A., Wuhrer M., Niessen W.M., Giera M. Amino acid analysis using chromatography-mass spectrometry: an inter platform comparison study. J. Pharm. Biomed. Anal. 2015, 114:398-407.
2. van den Ouweland J.M., Vogeser M., Bacher S. Vitamin D and metabolites measurement by tandem mass spectrometry. Rev. Endocr. Metab. Disord. 2013, 14:159-184.
3. Kushnir M.M., Rockwood A.L., Bergquist J. Liquid chromatography-tandem mass spectrometry applications in endocrinology. Mass Spectrom. Rev. 2010, 29:480-502.
4. Hoofnagle A.N. Quantitative clinical proteomics by liquid chromatography-tandem mass spectrometry: assessing the platform. Clin. Chem. 2010, 56:161-164.
5. Rauh M. LC-MS/MS for protein and peptide quantification in clinical chemistry. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2012, 883-884:59-67.
6. Zhang Y.V., Rockwood A. Impact of automation on mass spectrometry. Clin. Chim. Acta 2015, 450:298-303.
7. Hoofnagle A.N., Wener M.H. The fundamental flaws of immunoassays and potential solutions using tandem mass spectrometry. J. Immunol. Methods 2009, 347:3-11.
8. Becker J.O., Hoofnagle A.N. Replacing immunoassays with tryptic digestion-peptide immunoaffinity enrichment and LC-MS/MS. Bioanalysis 2012, 4:281-290.
9. Lippi G., Aloe R., Meschi T., Borghi L., Cervellin G. Interference from heterophilic antibodies in troponin testing. Case report and systematic review of the literature. Clin. Chim. Acta 2013, 426:79-84.
10. Bak M.J., Albrechtsen N.W., Pedersen J., Hartmann B., Christensen M., Vilsboll T., et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur. J. Endocrinol. 2014, 170:529-538.
11. Lapko V.N., Miller P.S., Brown G.P., Islam R., Peters S.K., Sukovaty R.L., et al. Sensitive glucagon quantification by immunochemical and LC-MS/MS methods. Bioanalysis 2013, 5:2957-2972.
12. Yabe D., Watanabe K., Sugawara K., Kuwata H., Kitamoto Y., Sugizaki K., et al. Comparison of incretin immunoassays with or without plasma extraction: incretin secretion in Japanese patients with type 2 diabetes. J. Diabetes Investig. 2012, 3:70-79.
13. Klee E.W., Bondar O.P., Goodmanson M.K., Trushin S.A., Singh R.J., Anderson N.L., Klee G.G. Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences. Am. J. Clin. Pathol. 2014, 141:527-533.
14. Singh R.J., Hines J.M., Lopez M.F., Krastins B., Hoofnagle A.N. Mass spectrometric immunoassay raises doubt for the existence of parathyroid hormone fragment 7-84. Clin. Chem. 2015, 61:558-560.
15. Seger C. Usage and limitations of liquid chromatography-tandem mass spectrometry (LC-MS/MS) in clinical routine laboratories. Wien. Med. Wochenschr. 2012, 162:499-504.
16. Strathmann F.G., Hoofnagle A.N. Current and future applications of mass spectrometry to the clinical laboratory. Am. J. Clin. Pathol. 2011, 136:609-616.
17. van den Ouweland J.M., Kema I.P. The role of liquid chromatography-tandem mass spectrometry in the clinical laboratory. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2012, 883-884:18-32.
18. Wu A.H., French D. Implementation of liquid chromatography/mass spectrometry into the clinical laboratory. Clin. Chim. Acta 2013, 420:4-10.
19. Vila-Rico M., Colome-Calls N., Martin-Castel L., Gay M., Azorin S., Vilaseca M., et al. Quantitative analysis of post-translational modifications in human serum transthyretin associated with familial amyloidotic polyneuropathy by targeted LC-MS and intact protein MS. J. Proteome 2015.
20. Trenchevska O., Schaab M.R., Nelson R.W., Nedelkov D. Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms. Methods 2015, 81:86-92.
21. Krastins B., Prakash A., Sarracino D.A., Nedelkov D., Niederkofler E.E., Kiernan U.A., et al. Rapid development of sensitive, high-throughput, quantitative and highly selective mass spectrometric targeted immunoassays for clinically important proteins in human plasma and serum. Clin. Biochem. 2013, 46:399-410.
22. Annesley T.M. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49:1041-1044.
23. Anderson L., Hunter C.L. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol. Cell. Proteomics 2006, 5:573-588.
24. Leung K.S., Fong B.M. LC-MS/MS in the routine clinical laboratory: has its time come?. Anal. Bioanal. Chem. 2014, 406:2289-2301.
25. Adaway J.E., Keevil B.G., Owen L.J. Liquid chromatography tandem mass spectrometry in the clinical laboratory. Ann. Clin. Biochem. 2015, 52:18-38.
26. Zhu P., Bowden P., Zhang D., Marshall J.G. Mass spectrometry of peptides and proteins from human blood. Mass Spectrom. Rev. 2011, 30:685-732.
27. Chappell D.L., Lassman M.E., McAvoy T., Lin M., Spellman D.S., Laterza O.F. Quantitation of human peptides and proteins via MS: review of analytically validated assays. Bioanalysis 2014, 6:1843-1857.
28. Grebe S.K., Singh R.J. LC-MS/MS in the clinical laboratory - where to from here?. Clin. Biochem. Rev. 2011, 32:5-31.
29. Scherl A. Clinical protein mass spectrometry. Methods 2015, 81:3-14.
30. Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin. Chem. 2015, 61:100-111.
31. Gilbertson J.A., Theis J.D., Vrana J.A., Lachmann H., Wechalekar A., Whelan C., et al. A comparison of immunohistochemistry and mass spectrometry for determining the amyloid fibril protein from formalin-fixed biopsy tissue. J. Clin. Pathol. 2015, 68:314-317.
32. Gallien S., Domon B. Detection and quantification of proteins in clinical samples using high resolution mass spectrometry. Methods 2015, 81:15-23.
33. Dillen L., Cools W., Vereyken L., Lorreyne W., Huybrechts T., de Vries R., et al. Comparison of triple quadrupole and high-resolution TOF-MS for quantification of peptides. Bioanalysis 2012, 4:565-579.
34. Ackermann B.L. Understanding the role of immunoaffinity-based mass spectrometry methods for clinical applications. Clin. Chem. 2012, 58:1620-1622.
35. Jeudy J., Salvador A., Simon R., Jaffuel A., Fonbonne C., Leonard J.F., et al. Overcoming biofluid protein complexity during targeted mass spectrometry detection and quantification of protein biomarkers by MRM cubed (MRM3). Anal. Bioanal. Chem. 2014, 406:1193-1200.
36. Wieringa G.E., Sturgeon C.M., Trainer P.J. The harmonisation of growth hormone measurements: taking the next steps. Clin. Chim. Acta 2014, 432:68-71.
37. Arsene C.G., Kratzsch J., Henrion A. Mass spectrometry - an alternative in growth hormone measurement. Bioanalysis 2014, 6:2391-2402.
38. Miller W.G., Bruns D.E., Hortin G.L., Sandberg S., Aakre K.M., McQueen M.J., et al. Current issues in measurement and reporting of urinary albumin excretion. Clin. Chem. 2009, 55:24-38.
39. Robbins D.C., Andersen L., Bowsher R., Chance R., Dinesen B., Frank B., et al. Report of the American Diabetes Association's task force on standardization of the insulin assay. Diabetes 1996, 45:242-256.
40. Kippen A.D., Cerini F., Vadas L., Stocklin R., Vu L., Offord R.E., Rose K. Development of an isotope dilution assay for precise determination of insulin, C-peptide, and proinsulin levels in non-diabetic and type II diabetic individuals with comparison to immunoassay. J. Biol. Chem. 1997, 272:12513-12522.
41. Kumar V., Barnidge D.R., Chen L.S., Twentyman J.M., Cradic K.W., Grebe S.K., Singh R.J. Quantification of serum 1-84 parathyroid hormone in patients with hyperparathyroidism by immunocapture in situ digestion liquid chromatography-tandem mass spectrometry. Clin. Chem. 2010, 56:306-313.
42. Lopez M.F., Rezai T., Sarracino D.A., Prakash A., Krastins B., Athanas M., et al. Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. Clin. Chem. 2010, 56:281-290.
43. Mannstadt M., Juppner H., Gardella T.J. Receptors for PTH and PTHrP: their biological importance and functional properties. Am. J. Phys. 1999, 277:F665-F675.
44. Mills T.A., Orloff M., Domingo-Vidal M., Cotzia P., Birbe R.C., Draganova-Tacheva R., et al. Parathyroid hormone-related peptide-linked hypercalcemia in a melanoma patient treated with Ipilimumab: hormone source and clinical and metabolic correlates. Semin. Oncol. 2015, 42:909-914.
45. Kushnir M.M., Rockwood A.L., Strathmann F.G., Frank E.L., Straseski J.A. Meikle AW. LC-MS/MS measurement of parathyroid hormone-related peptide. Clin. Chem. 2015, 218-226.
46. Bolstad N., Warren D.J., Bjerner J., Kravdal G., Schwettmann L., Olsen K.H., et al. Heterophilic antibody interference in commercial immunoassays; a screening study using paired native and pre-blocked sera. Clin. Chem. Lab. Med. 2011, 49:2001-2006.
47. Levinson S.S. Antibody multispecificity in immunoassay interference. Clin. Biochem. 1992, 25:77-87.
48. Bolstad N., Warren D.J., Nustad K. Heterophilic antibody interference in immunometric assays. Best Pract. Res. Clin. Endocrinol. Metab. 2013, 27:647-661.
49. Whitley R.J., Ain K.B. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Clin. Lab. Med. 2004, 24:29-47.
50. Harish K. Thyroglobulin: current status in differentiated thyroid carcinoma (review). Endocr. Regul. 2006, 40:53-67.
51. Demers L.M., Spencer C.A. Laboratory medicine practice guidelines: laboratory support for the diagnosis and monitoring of thyroid disease. Clin. Endocrinol. 2003, 58:138-140.
52. Kowarski A.A., Schneider J., Ben Galim E., Weldon V.V., Daughaday W.H. Growth failure with normal serum RIA-GH and low somatomedin activity: somatomedin restoration and growth acceleration after exogenous GH. J. Clin. Endocrinol. Metab. 1978, 47:461-464.
53. Bayer M.F., Kriss J.P. Immunoradiometric assay for serum thyroglobulin: semiquantitative measurement of thyroglobulin in antithyroglobulin-positive sera. J. Clin. Endocrinol. Metab. 1979, 49:557-564.
54. Hjiyiannakis P., Mundy J., Harmer C. Thyroglobulin antibodies in differentiated thyroid cancer. Clin. Oncol. (R. Coll. Radiol.) 1999, 11:240-244.
55. Preissner C.M., O'Kane D.J., Singh R.J., Morris J.C., Grebe S.K. Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. J. Clin. Endocrinol. Metab. 2003, 88:3069-3074.
56. Hoofnagle A.N., Becker J.O., Wener M.H., Heinecke J.W. Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin. Chem. 2008, 54:1796-1804.
57. Netzel B.C., Grebe S.K., Carranza Leon B.G., Castro M.R., Clark P.M., Hoofnagle A.N., et al. Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. J. Clin. Endocrinol. Metab. 2015, 100:E1074-E1083.
58. Pink D., Schoeler D., Lindner T., Thuss-Patience P.C., Kretzschmar A., Knipp H., et al. Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors: a report of two cases. J. Clin. Oncol. 2005, 23:6809-6811.
59. Ketha H., Singh R.J. Clinical assays for quantitation of insulin-like-growth-factor-1 (IGF1). Methods 2015, 81:93-98.
60. Krebs A., Wallaschofski H., Spilcke-Liss E., Kohlmann T., Brabant G., Volzke H., Nauck M. Five commercially available insulin-like growth factor I (IGF-I) assays in comparison to the former Nichols advantage IGF-I in a growth hormone treated population. Clin. Chem. Lab. Med. 2008, 46:1776-1783.
61. Bystrom C., Sheng S., Zhang K., Caulfield M., Clarke N.J., Reitz R. Clinical utility of insulin-like growth factor 1 and 2; determination by high resolution mass spectrometry. PLoS One 2012, 7.
62. Niederkofler E.E., Phillips D.A., Krastins B., Kulasingam V., Kiernan U.A., Tubbs K.A., et al. Targeted selected reaction monitoring mass spectrometric immunoassay for insulin-like growth factor 1. PLoS One 2013, 8.
63. Klee E.W., Bondar O.P., Goodmanson M.K., Trushin S.A., Bergstralh E.J., Singh R.J., et al. Serum concentrations of prostate-specific antigen measured using immune extraction, trypsin digestion, and tandem mass spectrometry quantification of LSEPAELTDAVK peptide. Arch. Pathol. Lab. Med. 2014, 138:1381-1386.
64. Simon R., Passeron S., Lemoine J., Salvador A. Hydrophilic interaction liquid chromatography as second dimension in multidimensional chromatography with an anionic trapping strategy: application to prostate-specific antigen quantification. J. Chromatogr. A 2014, 1354:75-84.
65. Mills J.R., Barnidge D.R., Murray D.L. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 2015, 81:56-65.
66. Zheng J., Mehl J., Zhu Y., Xin B., Olah T. Application and challenges in using LC-MS assays for absolute quantitative analysis of therapeutic proteins in drug discovery. Bioanalysis 2014, 6:859-879.
67. Ezan E., Dubois M., Becher F. Bioanalysis of recombinant proteins and antibodies by mass spectrometry. Analyst 2009, 134:825-834.
68. van dB I., Niessen W.M., van Dongen W.D. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2013, 929:161-179.
69. An B., Zhang M., Qu J. Toward sensitive and accurate analysis of antibody biotherapeutics by liquid chromatography coupled with mass spectrometry. Drug Metab. Dispos. 2014, 42:1858-1866.
70. Shen Y., Zhang G., Yang J., Qiu Y., McCauley T., Pan L., Wu J. Online 2D-LC-MS/MS assay to quantify therapeutic protein in human serum in the presence of pre-existing antidrug antibodies. Anal. Chem. 2015, 87:8555-8563.
71. Gong C., Zeng J., Akinsanya B., Jiang H., Mora J., Chilewski S., et al. Development and validation of an LC-MS/MS assay for the quantitation of a PEGylated anti-CD28 domain antibody in human serum: overcoming interference from antidrug antibodies and soluble target. Bioanalysis 2014, 6:2371-2383.
72. Chilewski S.D., Jiang H. Choosing the right bioanalytical assay platform(s) to support the PK assessment of protein biotherapeutic programs. Bioanalysis 2015, 7:1197-1199.
73. Neubert H., Muirhead D., Kabir M., Grace C., Cleton A., Arends R. Sequential protein and peptide immunoaffinity capture for mass spectrometry-based quantification of total human beta-nerve growth factor. Anal. Chem. 2013, 85:1719-1726.
74. Biarc J., Simon R., Fonbonne C., Leonard J.F., Gautier J.C., Pasquier O., et al. Absolute quantification of podocalyxin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-mass spectrometry. J. Chromatogr. A 2015, 1397:81-85.
75. Simon R., Lemoine J., Fonbonne C., Jaffuel A., Leonard J.F., Gautier J.C., et al. Absolute quantification of podocin, a potential biomarker of glomerular injury in human urine, by liquid chromatography-multiple reaction monitoring cubed mass spectrometry. J. Pharm. Biomed. Anal. 2014, 94:84-91.
76. Jaffuel A., Lemoine J., Aubert C., Simon R., Leonard J.F., Gautier J.C., et al. Optimization of liquid chromatography-multiple reaction monitoring cubed mass spectrometry assay for protein quantification: application to aquaporin-2 water channel in human urine. J. Chromatogr. A 2013, 1301:122-130.
77. Chappell D.L., Lee A.Y., Castro-Perez J., Zhou H., Roddy T.P., Lassman M.E., et al. An ultrasensitive method for the quantitation of active and inactive GLP-1 in human plasma via immunoaffinity LC-MS/MS. Bioanalysis 2014, 6:33-42.
78. Howard J.W., Kay R.G., Tan T., Minnion J., Ghatei M., Bloom S., Creaser C.S. Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma. Bioanalysis 2014, 6:3295-3309.
79. Morin L.P., Mess J.N., Garofolo F. Large-molecule quantification: sensitivity and selectivity head-to-head comparison of triple quadrupole with Q-TOF. Bioanalysis 2013, 5:1181-1193.
80. Lee A.Y., Chappell D.L., Bak M.J., Judo M., Liang L., Churakova T., et al. Multiplexed quantification of proglucagon-derived peptides by immunoaffinity enrichment and tandem mass spectrometry after a Meal tolerance test. Clin. Chem. 2016, 62:227-235.
81. Yi J., Warunek D., Craft D. Degradation and stabilization of peptide hormones in human blood specimens. PLoS One 2015, 10.
82. Hawkridge A.M., Muddiman D.C., Hebulein D.M., Cataliotti A., Burnett J.C. Effect of plasma protein depletion on BNP-32 recovery. Clin. Chem. 2008, 54:933-934.
83. Andrews G.L., Shuford C.M., Burnett J.C., Hawkridge A.M., Muddiman D.C. Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. J. Chromatogr. B Anal. Technol. Biomed. Life Sci. 2009, 877:948-954.
84. Hawkridge A.M., Heublein D.M., Bergen H.R., Cataliotti A., Burnett J.C., Muddiman D.C. Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:17442-17447.
85. McAvoy T., Lassman M.E., Spellman D.S., Ke Z., Howell B.J., Wong O., et al. Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin. Chem. 2014, 60:683-689.
86. Lancrajan I., Schneider-Stock R., Naschberger E., Schellerer V.S., Sturzl M., Enz R. Absolute quantification of DcR3 and GDF15 from human serum by LC-ESI MS. J. Cell. Mol. Med. 2015, 19:1656-1671.
87. Agger S.A., Marney L.C., Hoofnagle A.N. Simultaneous quantification of apolipoprotein A-I and apolipoprotein B by liquid-chromatography-multiple- reaction-monitoring mass spectrometry. Clin. Chem. 2010, 56:1804-1813.
88. Flood-Nichols S.K., Tinnemore D., Wingerd M.A., Abu-Alya A.I., Napolitano P.G., Stallings J.D., Ippolito D.L. Longitudinal analysis of maternal plasma apolipoproteins in pregnancy: a targeted proteomics approach. Mol. Cell. Proteomics 2013, 12:55-64.
89. Hoofnagle A.N., Becker J.O., Oda M.N., Cavigiolio G., Mayer P., Vaisar T. Multiple-reaction monitoring-mass spectrometric assays can accurately measure the relative protein abundance in complex mixtures. Clin. Chem. 2012, 58:777-781.
90. Kay R.G., Gregory B., Grace P.B., Pleasance S. The application of ultra-performance liquid chromatography/tandem mass spectrometry to the detection and quantitation of apolipoproteins in human serum. Rapid Commun. Mass Spectrom. 2007, 21:2585-2593.
91. Lassman M.E., McLaughlin T.M., Somers E.P., Stefanni A.C., Chen Z., Murphy B.A., et al. A rapid method for cross-species quantitation of apolipoproteins A1, B48 and B100 in plasma by ultra-performance liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2012, 26:101-108.
92. Simon R., Girod M., Fonbonne C., Salvador A., Clement Y., Lanteri P., et al. Total ApoE and ApoE4 isoform assays in an Alzheimer's disease case-control study by targeted mass spectrometry (n = 669): a pilot assay for methionine-containing proteotypic peptides. Mol. Cell. Proteomics 2012, 11:1389-1403.
93. Lassman M.E., McLaughlin T.M., Zhou H., Pan Y., Marcovina S.M., Laterza O., Roddy T.P. Simultaneous quantitation and size characterization of apolipoprotein(a) by ultra-performance liquid chromatography/mass spectrometry. Rapid Commun. Mass Spectrom. 2014, 28:1101-1106.
94. Lassman M.E., McAvoy T., Lee A.Y., Chappell D., Wong O., Zhou H., et al. Practical immunoaffinity-enrichment LC-MS for measuring protein kinetics of low-abundance proteins. Clin. Chem. 2014, 60:1217-1224.
95. Millar J.S., Reyes-Soffer G., Jumes P., Dunbar R.L., deGoma E.M., Baer A.L., et al. Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjects. J. Clin. Invest. 2015, 125:2510-2522.
96. Bateman R.J., Munsell L.Y., Morris J.C., Swarm R., Yarasheski K.E., Holtzman D.M. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 2006, 12:856-861.
97. Zhou H., Castro-Perez J., Lassman M.E., Thomas T., Li W., McLaughlin T., et al. Measurement of apo(a) kinetics in human subjects using a microfluidic device with tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2013, 27:1294-1302.
98. Cox J., Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu. Rev. Biochem. 2011, 80:273-299.
99. Gygi S.P., Aebersold R. Mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 2000, 4:489-494.
100. Junger M.A., Aebersold R. Mass spectrometry-driven phosphoproteomics: patterning the systems biology mosaic. Wiley Interdiscip. Rev. Dev. Biol. 2014, 3:83-112.
101. Sajic T., Liu Y., Aebersold R. Using data-independent, high-resolution mass spectrometry in protein biomarker research: perspectives and clinical applications. Proteomics Clin. Appl. 2015, 9:307-321.
102. Good D.M., Zurbig P., Argiles A., Bauer H.W., Behrens G., Coon J.J., et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 2010, 9:2424-2437.
103. Schanstra J.P., Zurbig P., Alkhalaf A., Argiles A., Bakker S.J., Beige J., et al. Diagnosis and prediction of CKD progression by assessment of urinary peptides. J. Am. Soc. Nephrol. 2015, 26:1999-2010.
104. Arentz G., Weiland F., Oehler M.K., Hoffmann P. State of the art of 2D DIGE. Proteomics Clin. Appl. 2015, 9:277-288.
105. Gygi S.P., Rist B., Gerber S.A., Turecek F., Gelb M.H., Aebersold R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 1999, 17:994-999.
106. Zhang Q., Tang N., Schepmoes A.A., Phillips L.S., Smith R.D., Metz T.O. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. J. Proteome Res. 2008, 7:2025-2032.
107. Paweletz C.P., Wiener M.C., Bondarenko A.Y., Yates N.A., Song Q., Liaw A., et al. Application of an end-to-end biomarker discovery platform to identify target engagement markers in cerebrospinal fluid by high resolution differential mass spectrometry. J. Proteome Res. 2010, 9:1392-1401.
108. Wiener M.C., Sachs J.R., Deyanova E.G., Yates N.A. Differential mass spectrometry: a label-free LC-MS method for finding significant differences in complex peptide and protein mixtures. Anal. Chem. 2004, 76:6085-6096.
109. Zhao X., Deyanova E.G., Lubbers L.S., Zafian P., Li J.J., Liaw A., et al. Differential mass spectrometry of rat plasma reveals proteins that are responsive to 17beta-estradiol and a selective estrogen receptor modulator PPT. J. Proteome Res. 2008, 7:4373-4383.
110. Hendrickson R.C., Lee A.Y., Song Q., Liaw A., Wiener M., Paweletz C.P., et al. High resolution discovery proteomics reveals candidate disease progression markers of Alzheimer's disease in human cerebrospinal fluid. PLoS One 2015, 10.
111. Guo T., Kouvonen P., Koh C.C., Gillet L.C., Wolski W.E., Rost H.L., et al. Rapid mass spectrometric conversion of tissue biopsy samples into permanent quantitative digital proteome maps. Nat. Med. 2015, 21:407-413.
112. Maiolica A., Junger M.A., Ezkurdia I., Aebersold R. Targeted proteome investigation via selected reaction monitoring mass spectrometry. J. Proteome 2012, 75:3495-3513.
113. Wu H.Y., Goan Y.G., Chang Y.H., Yang Y.F., Chang H.J., Cheng P.N., et al. Qualification and verification of serological biomarker candidates for lung adenocarcinoma by targeted mass spectrometry. J. Proteome Res. 2015.
114. Kuhn E., Whiteaker J.R., Mani D.R., Jackson A.M., Zhao L., Pope M.E., et al. Interlaboratory evaluation of automated, multiplexed peptide immunoaffinity enrichment coupled to multiple reaction monitoring mass spectrometry for quantifying proteins in plasma. Mol. Cell. Proteomics 2012, 11:M111.
115. Cox H.D., Lopes F., Woldemariam G.A., Becker J.O., Parkin M.C., Thomas A., et al. Interlaboratory agreement of insulin-like growth factor 1 concentrations measured by mass spectrometry. Clin. Chem. 2014, 60:541-548.
116. Prakash A., Rezai T., Krastins B., Sarracino D., Athanas M., Russo P., et al. Interlaboratory reproducibility of selective reaction monitoring assays using multiple upfront analyte enrichment strategies. J. Proteome Res. 2012, 11:3986-3995.
117. Camerini S., Mauri P. The role of protein and peptide separation before mass spectrometry analysis in clinical proteomics. J. Chromatogr. A 2015, 1381:1-12.
118. Gregorich Z.R., Chang Y.H., Ge Y. Proteomics in heart failure: top-down or bottom-up?. Pflugers Arch. 2014, 466:1199-1209.
119. Sarsby J., Martin N.J., Lalor P.F., Bunch J., Cooper H.J. Top-down and bottom-up identification of proteins by liquid extraction surface analysis mass spectrometry of healthy and diseased human liver tissue. J. Am. Soc. Mass Spectrom. 2014, 25:1953-1961.